SUPPLEMENT

Q2 2021 — Reconciliation of Non-GAAP Financial Measures

Q2 2021PDF · 6 pages191 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020 	2021 	2020
Net Earnings, after tax- as reported 	$6,278 	$3,626 	$12,475 	$9,422
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,202 	1,127 	2,417 	2,245
Litigation related 	(23) 	613 	(23) 	733
IPR&D 	- 	6 	- 	6
Restructuring related 	108 	115 	212 	233
Acquisition, integration and divestiture related ¹ 	14 	29 	(524) 	(933)
Unrealized (gains)/losses on securities 	(243) 	(533) 	(208) 	(206)
Medical Device Regulation 	56 	37 	102 	51
Other 	- 	3 	- 	3
Tax Adjustments
Tax impact on special item adjustments 2 	(135) 	(253) 	(248) 	(520)
Tax legislation and other tax related 	(632) 	(324) 	(654) 	(434)
Adjusted Net Earnings, after tax 	$6,625 	$4,446 	$13,549 	$10,600
Average shares outstanding (Diluted) 	2,671.6 	2,665.5 	2,674.0 	2,671.0
Adjusted net earnings per share (Diluted) 	$2.48 	$1.67 	$5.07 	$3.97
Operational adjusted net earnings per share (Diluted) 	$2.42 	$4.91
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Second Quarter 	Six Months Ended
Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture
of two Pharmaceutical brands outside of the U.S. The six months of 2020 primarily includes a $983M Contingent
Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health
acquisition.

-- 1 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	13.3% 	17.2% 	62.7% 	27.1%
U.S. 	12.4% 	12.2% 	77.2% 	24.9%
International 	14.1% 	23.7% 	51.6% 	29.5%
WW Currency 	4.1 	3.6 	5.5 	4.1
U.S. 	- 	- 	- 	-
International 	7.8 	8.3 	9.7 	8.6
WW Operational 	9.2% 	13.6% 	57.2% 	23.0%
U.S. 	12.4% 	12.2% 	77.2% 	24.9%
International 	6.3% 	15.4% 	41.9% 	20.9%
General Surgery
Advanced Sterilization Products 	1.2 	0.2
U.S. 	0.0 	0.0
International 	1.9 	0.4
All Other Acquisitions and Divestitures 	0.8 	0.6 	0.3 	0.6
U.S. 	0.6 	(0.1) 	0.7 	0.1
International 	1.1 	1.5 	0.0 	1.0
WW Adjusted Operational 	10.0% 	14.1% 	58.7% 	23.8%
U.S. 	13.0% 	12.1% 	77.9% 	25.1%
International 	7.4% 	16.8% 	43.8% 	22.4%
Adjusted Operational Sales Growth
SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	5.2% 	13.3% 	32.7% 	16.9%
U.S. 	2.0% 	9.3% 	33.5% 	13.8%
International 	8.1% 	18.3% 	31.9% 	20.3%
WW Currency 	2.5 	3.0 	4.0 	3.2
U.S. 	- 	- 	- 	-
International 	4.8 	6.9 	7.4 	6.6
WW Operational 	2.7% 	10.3% 	28.7% 	13.7%
U.S. 	2.0% 	9.3% 	33.5% 	13.8%
International 	3.3% 	11.4% 	24.5% 	13.7%
General Surgery
Advanced Sterilization Products 	0.8 	0.2
U.S. 	0.0 	0.0
International 	1.5 	0.4
All Other Acquisitions and Divestitures 	0.6 	0.5 	0.2 	0.4
U.S. 	0.5 	(0.1) 	0.5 	0.1
International 	0.7 	1.2 	0.0 	0.8
WW Adjusted Operational 	3.3% 	10.7% 	29.7% 	14.4%
U.S. 	2.5% 	9.2% 	33.9% 	13.9%
International 	4.0% 	12.6% 	26.0% 	14.8%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL
Segments

-- 3 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income Before Tax by Segment 	$ 	804 	32 	4,356 	4,514 	1,746 	(354) 	(244) 	(252) 	6,662 	3,940
% to Sales 	21.5% 	1.0% 	34.6% 	42.0% 	25.0% 	-8.3% 	-1.0% 	-1.4% 	28.6% 	21.5%
Intangible asset amortization expense 	105 	102 	842 	779 	255 	246 	- 	- 	1,202 	1,127
In-process research and development 	- 	- 	- 	- 	- 	6 	- 	- 	- 	6
Litigation related 	122 	638 	(81) 	(58) 	(64) 	33 	- 	- 	(23) 	613
- 	- 	-
Unrealized loss/(gain) on securities 	(18) 	- 	(151) 	(522) 	(74) 	(11) 	- 	- 	(243) 	(533)
Restructuring related 	27 	20 	17 	21 	64 	74 	- 	- 	108 	115
Acquisition, integration and divestiture related 	- 	- 	- 	10 	14 	19 	- 	- 	14 	29
Medical Device Regulation 	- 	- 	- 	- 	56 	37 	- 	- 	56 	37
Other 	- 	- 	- 	- 	- 	3 	- 	- 	- 	3
Adjusted Income Before Tax by Segment 	$ 	1,040 	792 	4,983 	4,744 	1,997 	53 	(244) 	(252) 	7,776 	5,337
% to Sales 	27.8% 	24.0% 	39.6% 	44.1% 	28.6% 	1.2% 	-1.0% 	-1.4% 	33.4% 	29.1%
*Estimated as of 07/21/2021.
Q2 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 4 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income Before Tax by Segment 	$ 	1,592 	802 	9,579 	8,348 	3,375 	1,671 	(455) 	(372) 	14,091 	10,449
% to Sales 	21.9% 	11.6% 	38.6% 	38.1% 	24.9% 	16.4% 	-1.0% 	-1.0% 	30.9% 	26.8%
Intangible asset amortization expense 	211 	202 	1,698 	1,550 	508 	493 	- 	- 	2,417 	2,245
In-process research and development 	- 	- 	- 	- 	- 	6 	- 	- 	- 	6
Litigation related 	122 	638 	(81) 	35 	(64) 	60 	- 	- 	(23) 	733
Unrealized loss/(gain) on securities 	(20) 	1 	(114) 	(208) 	(74) 	1 	- 	- 	(208) 	(206)
Restructuring related 	55 	38 	37 	41 	120 	154 	- 	- 	212 	233
Acquisition, integration and divestiture related 	- 	- 	(570) 	19 	46 	(952) 	- 	- 	(524) 	(933)
Medical Device Regulation 	- 	- 	- 	- 	102 	51 	- 	- 	102 	51
Other 	- 	- 	- 	- 	- 	3 	- 	- 	- 	3
Adjusted Income Before Tax by Segment 	$ 	1,960 	1,681 	10,549 	9,785 	4,013 	1,487 	(455) 	(372) 	16,067 	12,581
% to Sales 	26.9% 	24.3% 	42.5% 	44.7% 	29.6% 	14.6% 	-1.0% 	-1.0% 	35.2% 	32.2%
*Estimated as of 07/21/2021.
Q2 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 5 of 6 --

Second Quarter 	Second Quarter
July 4, 2021
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
July 4, 2021
Non-GAAP
Cost of products sold 	7,587	$ 	(1,202) 	(20) 	(20) 	6,345
Selling, marketing and admin expenses 	6,073 	(6) 	6,067
Research and development expense 	3,394 	- 	(30) 	3,364
Other (Income) / Expense 	(488) 	- 	23 	(32) 	(14) 	243 	- 	(268)
In-process research and development 	- 	- 	-
Restructuring 	56 	(56) 	-
Provision for taxes on income 	384 	163 	(1) 	- 	17 	3 	(57) 	10 	632 	- 	1,151
Net Earnings 	6,278 	1,039 	(22) 	- 	91 	11 	(186) 	46 	(632) 	- 	6,625
Second Quarter 	Second Quarter
June 28, 2020
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
June 28, 2020
Non-GAAP
Cost of products sold 	6,579	$ 	(1,127) 	(22) 	(8) 	5,422
Selling, marketing and admin expenses 	4,993 	(6) 	4,987
Research and development expense 	2,707 	(5) 	(23) 	2,679
Other (Income) / Expense 	24 	- 	(613) 	(32) 	(24) 	533 	(3) 	(115)
In-process research and development 	6 	(6) 	-
Restructuring 	61 	(61) 	-
Provision for taxes on income 	314 	217 	123 	1 	22 	4 	(122) 	7 	324 	1 	891
Net Earnings 	3,626 	910 	490 	5 	93 	25 	(411) 	30 	(324) 	2 	4,446
Six Months 	Six Months
July 4, 2021
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
July 4, 2021
Non-GAAP
Cost of products sold 	14,650	$ 	(2,417) 	(47) 	(37) 	12,149
Selling, marketing and admin expenses 	11,505 	(11) 	11,494
Research and development expense 	6,572 	- 	(54) 	6,518
Other (Income) / Expense 	(1,370) 	- 	23 	(56) 	524 	208 	- 	(671)
In-process research and development 	- 	- 	-
Restructuring 	109 	(109) 	-
Provision for taxes on income 	1,616 	340 	(1) 	- 	37 	(98) 	(49) 	19 	654 	- 	2,518
Net Earnings 	12,475 	2,077 	(22) 	- 	175 	(426) 	(159) 	83 	(654) 	- 	13,549
Six Months 	Six Months
June 28, 2020
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
June 28, 2020
Non-GAAP
Cost of products sold 	13,641	$ 	(2,245) 	(37) 	(22) 	11,337
Selling, marketing and admin expenses 	10,196 	(6) 	10,190
Research and development expense 	5,287 	(5) 	(23) 	5,259
Other (Income) / Expense 	(655) 	- 	(733) 	(77) 	938 	206 	(3) 	(324)
In-process research and development 	6 	(6) 	-
Restructuring 	119 	(119) 	-
Provision for taxes on income 	1,027 	363 	143 	1 	43 	7 	(47) 	9 	434 	1 	1,981
Net Earnings 	9,422 	1,882 	590 	5 	190 	(940) 	(159) 	42 	(434) 	2 	10,600
(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. 2020 primarily includes a $983 million Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
In-process
research and
development
Acquisition, integration and
divestiture related (1)
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related
In-process
research and
development
Acquisition, integration and
divestiture related
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related
Year to Date
In-process
research and
development
Acquisition, integration and
divestiture related (1)
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
Acquisition, integration and
divestiture related
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related

-- 6 of 6 --